RLAY [NASD]
Relay Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.69 Insider Own1.20% Shs Outstand120.89M Perf Week6.32%
Market Cap2.60B Forward P/E- EPS next Y-3.05 Insider Trans-20.17% Shs Float115.44M Perf Month51.84%
Income-290.50M PEG- EPS next Q-0.70 Inst Own- Short Float / Ratio16.16% / 14.22 Perf Quarter-0.55%
Sales1.70M P/S1527.22 EPS this Y-49.40% Inst Trans1.58% Short Interest18.66M Perf Half Y7.25%
Book/sh9.01 P/B2.43 EPS next Y-11.30% ROA-28.90% Target Price36.20 Perf Year2.48%
Cash/sh8.88 P/C2.46 EPS next 5Y- ROE-33.00% 52W Range12.65 - 35.36 Perf YTD46.45%
Dividend- P/FCF- EPS past 5Y- ROI-40.60% 52W High-38.12% Beta-
Dividend %- Quick Ratio15.20 Sales past 5Y- Gross Margin- 52W Low72.96% ATR1.21
Employees320 Current Ratio15.20 Sales Q/Q-57.10% Oper. Margin- RSI (14)71.27 Volatility6.10% 6.81%
OptionableYes Debt/Eq0.00 EPS Q/Q-15.60% Profit Margin- Rel Volume1.10 Prev Close20.19
ShortableYes LT Debt/Eq0.00 EarningsNov 03 AMC Payout- Avg Volume1.31M Price21.88
Recom2.10 SMA2021.84% SMA5023.74% SMA2007.76% Volume1,437,757 Change8.37%
Sep-30-22Initiated Barclays Equal Weight $23
Sep-02-22Initiated Stifel Buy $40
Jun-06-22Initiated Jefferies Underperform $13
Feb-01-22Initiated Berenberg Buy $45
Jul-21-21Initiated BofA Securities Buy $50
Dec-15-20Reiterated H.C. Wainwright Buy $54 → $57
Dec-08-20Initiated JMP Securities Mkt Outperform $66
Nov-05-20Initiated H.C. Wainwright Buy $54
Aug-10-20Initiated JP Morgan Neutral $36
Aug-10-20Initiated Guggenheim Buy $48
Show Previous Ratings
Jan-13-23 11:11AM
Jan-03-23 07:30AM
Dec-31-22 08:53AM
Nov-24-22 08:02AM
Nov-17-22 01:58PM
07:30AM Loading…
Nov-07-22 07:30AM
Nov-03-22 06:35PM
04:05PM
Oct-27-22 04:05PM
Oct-14-22 10:14AM
Sep-26-22 07:30AM
Sep-23-22 07:30AM
Sep-12-22 09:30PM
07:00AM
06:30AM
09:45AM Loading…
Sep-11-22 09:45AM
Sep-08-22 04:06PM
10:25AM
Aug-30-22 11:15AM
Aug-25-22 02:48PM
Aug-18-22 04:05PM
Aug-04-22 04:05PM
Jul-28-22 04:05PM
Jun-27-22 06:00AM
Jun-16-22 07:30AM
May-26-22 07:30AM
May-07-22 09:59AM
May-05-22 04:05PM
May-03-22 07:30AM
Apr-28-22 04:05PM
04:05PM Loading…
Feb-24-22 04:05PM
Feb-17-22 04:05PM
Feb-10-22 11:51AM
Feb-02-22 07:30AM
Jan-04-22 07:30AM
Jan-03-22 07:30AM
Dec-22-21 11:11AM
Dec-18-21 12:38AM
Dec-10-21 07:30AM
Nov-17-21 11:39AM
Nov-16-21 12:36PM
Nov-10-21 04:05PM
Nov-04-21 04:05PM
08:14AM
Oct-27-21 01:23PM
04:50AM
Oct-15-21 09:01AM
Oct-12-21 09:58PM
04:27AM
Oct-11-21 04:15PM
Oct-08-21 12:24PM
06:00AM
Oct-07-21 08:50AM
Sep-13-21 06:00AM
Aug-18-21 10:27AM
Aug-15-21 04:06AM
Aug-12-21 04:05PM
Aug-05-21 04:05PM
Jul-20-21 10:48PM
Jul-19-21 09:26AM
Jun-02-21 06:00AM
May-14-21 06:00AM
May-13-21 04:05PM
May-10-21 06:00AM
May-05-21 06:00AM
May-03-21 06:00AM
Apr-16-21 11:31AM
06:00AM
Apr-14-21 05:57AM
Mar-25-21 04:05PM
Mar-10-21 04:30PM
Feb-04-21 04:05PM
Jan-14-21 04:26AM
Jan-06-21 05:00PM
06:00AM
Dec-16-20 10:36PM
Dec-14-20 06:00AM
Nov-12-20 04:05PM
Oct-16-20 10:53AM
Sep-03-20 04:05PM
Aug-27-20 06:50AM
Aug-16-20 08:59AM
Aug-11-20 06:40AM
Aug-06-20 06:07PM
Jul-20-20 04:05PM
Jul-17-20 04:17PM
Jul-16-20 04:28PM
01:25PM
12:02PM
Jul-15-20 08:51PM
07:34AM
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel SanjivPresident and CEOJan 19Option Exercise5.0428,000141,120282,554Jan 19 08:33 PM
Patel SanjivPresident and CEOJan 19Sale20.0228,000560,560254,554Jan 19 08:33 PM
Patel SanjivPresident and CEOJan 18Option Exercise5.0428,000141,120282,554Jan 19 08:33 PM
Patel SanjivPresident and CEOJan 18Sale20.8728,000584,360254,554Jan 19 08:33 PM
Patel SanjivPresident and CEOJan 17Option Exercise5.0428,000141,120282,554Jan 19 08:33 PM
Patel SanjivPresident and CEOJan 17Sale20.2328,000566,440254,554Jan 19 08:33 PM
Adams BrianChief Legal OfficerJan 12Sale20.009,994199,88051,531Jan 13 04:05 PM
Catinazzo ThomasChief Financial OfficerDec 27Sale14.494456,44850,231Dec 28 04:13 PM
Bergstrom Donald APresident, R&DDec 27Sale14.4998014,20085,886Dec 28 04:09 PM
Adams BrianChief Legal OfficerDec 27Sale14.492954,27561,525Dec 28 04:07 PM
Patel SanjivPresident and CEONov 10Option Exercise4.4428,000124,399272,729Nov 10 05:13 PM
Patel SanjivPresident and CEONov 10Sale20.0028,000560,000254,554Nov 10 05:13 PM
Patel SanjivPresident and CEONov 08Option Exercise4.1214,00057,680268,554Nov 10 05:13 PM
Patel SanjivPresident and CEONov 08Sale20.1814,000282,520254,554Nov 10 05:13 PM
Bergstrom Donald APresident, R&DNov 01Option Exercise4.128,00032,96094,866Nov 01 05:58 PM
Bergstrom Donald APresident, R&DNov 01Sale22.758,000182,00086,866Nov 01 05:58 PM
Bergstrom Donald APresident, R&DOct 28Sale21.541,81739,13886,866Nov 01 05:58 PM
Adams BrianChief Legal OfficerOct 28Sale21.5472815,68161,820Nov 01 05:56 PM
Porter AndyChief Administrative OfficerOct 28Sale21.544489,65045,164Nov 01 06:03 PM
Catinazzo ThomasChief Financial OfficerOct 28Sale21.541,09923,67250,676Nov 01 06:01 PM
Patel SanjivPresident and CEOOct 13Option Exercise4.1214,00057,680268,554Oct 13 06:09 PM
Patel SanjivPresident and CEOOct 13Sale20.5814,000288,120254,554Oct 13 06:09 PM
Patel SanjivPresident and CEOOct 12Option Exercise4.1214,00057,680268,554Oct 13 06:09 PM
Patel SanjivPresident and CEOOct 12Sale21.1814,000296,520254,554Oct 13 06:09 PM
Patel SanjivPresident and CEOOct 11Option Exercise4.1214,00057,680268,554Oct 13 06:09 PM
Patel SanjivPresident and CEOOct 11Sale21.3614,000299,040254,554Oct 13 06:09 PM
Bergstrom Donald APresident, R&DOct 03Option Exercise4.128,00032,96096,683Oct 04 04:22 PM
Bergstrom Donald APresident, R&DOct 03Sale22.438,000179,44088,683Oct 04 04:22 PM
Porter AndyChief Administrative OfficerSep 27Sale22.732595,88745,612Sep 29 05:14 PM
Catinazzo ThomasChief Financial OfficerSep 27Sale22.7344310,06951,775Sep 29 05:10 PM
Bergstrom Donald APresident, R&DSep 27Sale22.7397622,18488,683Sep 29 05:07 PM
Adams BrianChief Legal OfficerSep 27Sale22.732946,68362,548Sep 29 05:04 PM
Patel SanjivPresident and CEOSep 15Option Exercise4.1214,00057,680268,554Sep 15 09:02 PM
Patel SanjivPresident and CEOSep 15Sale23.8014,000333,200254,554Sep 15 09:02 PM
Patel SanjivPresident and CEOSep 14Option Exercise4.1214,00057,680268,554Sep 15 09:02 PM
Patel SanjivPresident and CEOSep 14Sale23.4714,000328,580254,554Sep 15 09:02 PM
Patel SanjivPresident and CEOSep 13Option Exercise4.1214,00057,680268,554Sep 15 09:02 PM
Patel SanjivPresident and CEOSep 13Sale25.4514,000356,300254,554Sep 15 09:02 PM
Bergstrom Donald APresident, R&DSep 08Option Exercise4.1225,000103,000114,659Sep 08 08:22 PM
Catinazzo ThomasChief Financial OfficerSep 08Option Exercise4.1226,257108,17978,475Sep 08 08:26 PM
Murcko MarkDirectorSep 08Sale29.9525,000748,750996,952Sep 08 08:31 PM
Catinazzo ThomasChief Financial OfficerSep 08Sale30.0026,257787,71052,218Sep 08 08:26 PM
Bergstrom Donald APresident, R&DSep 08Sale30.0025,000750,00089,659Sep 08 08:22 PM
Bergstrom Donald APresident, R&DSep 02Option Exercise4.124,90020,18894,559Sep 02 05:47 PM
Bergstrom Donald APresident, R&DSep 02Sale25.464,900124,75489,659Sep 02 05:47 PM
Bergstrom Donald APresident, R&DSep 01Option Exercise4.128,10033,37297,759Sep 01 08:26 PM
Bergstrom Donald APresident, R&DSep 01Sale23.078,100186,86789,659Sep 01 08:26 PM
Bergstrom Donald APresident, R&DAug 24Option Exercise4.1215,00061,800104,659Aug 25 05:23 PM
Bergstrom Donald APresident, R&DAug 24Sale25.0015,000375,00089,659Aug 25 05:23 PM
Bergstrom Donald APresident, R&DAug 05Option Exercise4.128,00032,96097,659Aug 08 05:38 PM
Bergstrom Donald APresident, R&DAug 05Sale20.008,000160,00089,659Aug 08 05:38 PM
Porter AndyChief Administrative OfficerJul 28Sale21.274529,61445,871Jul 29 04:57 PM
Catinazzo ThomasChief Financial OfficerJul 28Sale21.2673415,60552,218Jul 29 04:53 PM
Bergstrom Donald APresident, R&DJul 28Sale21.271,83539,03089,659Jul 29 04:45 PM
Adams BrianChief Legal OfficerJul 28Sale21.2773415,61262,842Jul 29 04:42 PM
Bergstrom Donald APresident, R&DJul 06Option Exercise4.128,00032,96099,494Jul 08 04:17 PM
Bergstrom Donald APresident, R&DJul 06Sale20.008,000160,00091,494Jul 08 04:17 PM
Porter AndyChief Administrative OfficerJun 27Sale20.312655,38246,323Jun 28 06:03 PM
Catinazzo ThomasChief Financial OfficerJun 27Sale20.313006,09352,952Jun 28 05:59 PM
Adams BrianChief Legal OfficerJun 27Sale20.313006,09363,576Jun 28 05:56 PM
Bergstrom Donald APresident, R&DJun 27Sale20.3199920,29091,494Jun 28 05:53 PM
Bergstrom Donald APresident, R&DJun 24Option Exercise4.128,00032,960100,493Jun 28 05:53 PM
Bergstrom Donald APresident, R&DJun 24Sale20.008,000160,00092,493Jun 28 05:53 PM
Bergstrom Donald APresident, R&DMay 02Option Exercise4.1213,00053,560105,493May 02 08:24 PM
Bergstrom Donald APresident, R&DMay 02Sale24.6213,000320,06092,493May 02 08:24 PM
Bergstrom Donald APresident, R&DApr 28Sale25.571,81146,30792,493May 02 08:24 PM
Porter AndyChief Administrative OfficerApr 28Sale25.5743511,12346,588May 02 08:13 PM
Catinazzo ThomasChief Financial OfficerApr 28Sale25.5772518,53853,252May 02 08:07 PM
Adams BrianChief Legal OfficerApr 28Sale25.5770818,10463,876May 02 08:03 PM
Patel SanjivPresident and CEOApr 14Option Exercise4.5828,000128,240267,740Apr 14 09:20 PM
Patel SanjivPresident and CEOApr 14Sale30.5128,000854,280253,740Apr 14 09:20 PM
Patel SanjivPresident and CEOApr 13Option Exercise4.5828,000128,240267,740Apr 14 09:20 PM
Patel SanjivPresident and CEOApr 13Sale31.9528,000894,600253,740Apr 14 09:20 PM
Patel SanjivPresident and CEOApr 12Option Exercise4.1228,000115,360281,740Apr 14 09:20 PM
Patel SanjivPresident and CEOApr 12Sale31.8028,000890,400253,740Apr 14 09:20 PM
Bergstrom Donald APresident, R&DApr 01Option Exercise4.1218,00074,160112,304Apr 05 05:32 PM
Bergstrom Donald APresident, R&DApr 01Sale30.3218,000545,76094,304Apr 05 05:32 PM
Porter AndyChief Administrative OfficerMar 29Sale29.872948,78247,023Mar 31 05:49 PM
Catinazzo ThomasChief Financial OfficerMar 29Sale29.872828,42353,977Mar 31 05:45 PM
Adams BrianChief Legal OfficerMar 29Sale29.873339,94764,584Mar 31 05:37 PM
Bergstrom Donald APresident, R&DMar 29Sale29.8762218,57994,304Mar 31 05:41 PM
Catinazzo ThomasChief Financial OfficerMar 24Option Exercise4.1213,28654,73867,545Mar 28 08:18 PM
Bergstrom Donald APresident, R&DMar 24Option Exercise4.1210,00041,200104,926Mar 28 08:11 PM
Catinazzo ThomasChief Financial OfficerMar 24Sale30.0013,286398,58054,259Mar 28 08:18 PM
Bergstrom Donald APresident, R&DMar 24Sale30.0010,000300,00094,926Mar 28 08:11 PM
Bergstrom Donald APresident, R&DMar 10Option Exercise4.1210,00041,200104,926Mar 11 07:02 PM
Bergstrom Donald APresident, R&DMar 10Sale25.0010,000250,00094,926Mar 11 07:02 PM
Bergstrom Donald APresident, R&DMar 01Option Exercise4.128,00032,960102,926Mar 03 05:31 PM
Bergstrom Donald APresident, R&DMar 01Sale23.888,000191,04094,926Mar 03 05:31 PM
Bergstrom Donald APresident, R&DFeb 22Option Exercise4.128,00032,960117,920Feb 22 09:01 PM
Bergstrom Donald APresident, R&DFeb 22Sale20.9422,994481,57794,926Feb 22 09:01 PM